EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSGEVG00005019739
Gene Symbol: PIK3R3
3 Cross references
274 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSGEVG00005014622
Gene Symbol: PIK3R5
3 Cross references
256 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phospholipase A2 Group Iia

Ensembl ID : ENSGEVG00005006116
Gene Symbol: PLA2G2A
1 Cross references
164 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phospholipase A2 Group Vii

Ensembl ID : ENSGEVG00005010524
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSGEVG00005003700
Gene Symbol: GART
2 Cross references
129 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Plasminogen Activator, Tissue Type

Ensembl ID : ENSGEVG00005020456
Gene Symbol: PLAT
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Activating Factor Receptor

Ensembl ID : ENSGEVG00005012860
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSGEVG00005014354
Gene Symbol: PDGFRA
1 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSGEVG00005004021
Gene Symbol: PDGFRB
1 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSGEVG00005001493
Gene Symbol: PDGFB
1 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Polo Like Kinase 1

Ensembl ID : ENSGEVG00005014794
Gene Symbol: PLK1
1 Cross references
187 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Polo Like Kinase 4

Ensembl ID : ENSGEVG00005011577
Gene Symbol: PLK4
1 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).